Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-PD-L1 Antibody-APC (1D337) is a APC-conjugated Mouse antibody targeting PD-L1. Anti-PD-L1 Antibody-APC (1D337) can be used in FCM.
Description | Anti-PD-L1 Antibody-APC (1D337) is a APC-conjugated Mouse antibody targeting PD-L1. Anti-PD-L1 Antibody-APC (1D337) can be used in FCM. |
Ig Type | Monoclonal Mouse IgG1 |
Clone | 1D337 |
Reactivity | Human |
Verified Activity | Flow cytometric analysis of Human PDL1(CD274) expression on HCC827 cells. Cells were stained with APC-conjugated anti-Human PDL1(CD274). The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells. |
Application | FCM |
Recommended Dose | 5 μl/Test, 0.1 mg/ml |
Antibody Type | Monoclonal |
Host Species | Mouse |
Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human PD-L1/B7-H1/CD274 (rh PD-L1/B7-H1/CD274; TMPY-04343; NP_054862.1; Met1-Thr239) and conjugated with APC under optimum conditions, the unreacted APC was removed. |
Purification | Protein A |
Appearance | Liquid |
Formulation | PBS solution containing 0.5% BSA and 0.03%ProClin300 |
Research Background | Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Blockade: Blocking AntibodiImmune Checkpoint Blockade: PD-L1 / B7-H1 / CImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: ICC AntibodiesImmune Checkpoint Detection: IHC AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyPD-L1 / B7-H1 / CD274 Immune Checkpoint ProteTargeted Therapy |
Conjucates | APC |
Others Formats | Unconjugated/FITC/PE |
Antibody Types Available | 4 |
Immunogen | Recombinant Human PD-L1/B7-H1/CD274 Protein (TMPY-04343) |
Antigen Species | Human |
Biology Area | Cancer Drug Targets |
Stability & Storage | Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.